Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
03. Mai 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting
22. April 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Webcast to be Held Tuesday, May 4, 2021 at 2:00 p.m. EDT Webcast Will Feature Key Opinion Leader, Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of...
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
20. April 2021 07:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced the nominations of Sir Michael Rawlins and Joel S. Marcus to stand for election to the...
Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting
12. April 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Our research has demonstrated that the phosphodiesterase type 1 (PDE1) enzyme modulates the immune system by reducing macrophage and microglial activity with demonstrated effects in neuroinflammatory...
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
25. Februar 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Successfully launched CAPLYTA® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19. CAPLYTA achieved net product revenues of $12.4 million and...
Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
24. Februar 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients,...
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
22. Februar 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
ITCI submits Supplemental New Drug Applications (sNDAs) for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults.If...
Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
19. Februar 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast
17. Februar 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
21. Januar 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to...